Journal of Medicinal Chemistry · 2008 · 198 citations · 21 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoverySynthetic Medicinal ChemistryHormone ReceptorsHormone StructureLigand BindingLigand-based DesignPotency OptimizationReceptor PharmacologyAntagonist ActivityAntagonist PotencyHormone Receptor ModulationHormone Receptor PharmacologyProgesterone PharmacologyProgesterone Receptor ModulationProgesterone Receptor SignalingProgesterone Receptors
We have continued to explore the 3,3-dialkyl-5-aryloxindole series of progesterone receptor (PR) modulators looking for new agents to be used in female healthcare: contraception, fibroids, endometriosis, and certain breast cancers. Previously we reported that subtle structural changes with this and related templates produced functional switches between agonist and antagonist properties ( Fensome et al. Biorg. Med. Chem. Lett. 2002, 12, 3487; 2003, 13, 1317 ). We herein report a new functional switch within the 5-(2-oxoindolin-5-yl)-1 H-pyrrole-2-carbonitrile class of compounds. We found that the size of the 3,3-dialkyl substituent is important for controlling the functional response; thus small groups (dimethyl) afford potent PR antagonists, whereas larger groups (spirocyclohexyl) are PR agonists. The product from our optimization activities in cell-based systems and also for kinetic properties in rodents and nonhuman primates was 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1 H-indol-5-yl)-1-methyl-1 H-pyrrole-2-carbonitrile 27 (WAY-255348), which demonstrated potent and robust activity on PR antagonist and contraceptive end points in the rat and also in cynomolgus and rhesus monkeys including ovulation inhibition, menses induction, and reproductive tract morphology.
21
GAL4 fusion vectors for expression in yeast or mammalian cells
Ivan Sadowski, Brendan Bell, Peter Broad et al. · Gene · 1992 · 211 citations
Audrey Brown, Linan Cheng, Suiqing Lin et al. · The Journal of Clinical Endocrinology & Metabolism · 2002 · 108 citations